Stada has struck a licensing and commercialization deal with Sweden’s Calliditas worth at least €97.5m ($114.8m) covering a novel oral formulation of budesonide intended to treat rare chronic autoimmune kidney disease Immunoglobulin A Nephropathy in Europe.
Insisting that the partnership for the oral orphan-drug candidate “combines Calliditas’ drug-delivery expertise with Stada’s go-to-partner strategy and pan-European marketing...





